# MONARCH 2 (NCT02107703)

> A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02107703
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Breast Neoplasms
- Interventions: Abemaciclib; Fulvestrant; Placebo
- Enrollment: 669
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- YouTube: 43
- Podcasts: 25
- X threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=monarch-2-nct02107703

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02107703", "email": "<work email>"}; the inbox owner confirms by the emailed link.